EyeWorld Asia-Pacific September 2013 Issue

29 EWAP CAtArACt/IOL September 2013 TECHNOLAS Perfect Vision GmbH – A Bausch + Lomb Company Messerschmittstr. 1+3, Munich, Germany Regional Office Asia-Pacific Technolas Singapore Pte Ltd 101 Thomson Road, #27-03A United Square Singapore 307591 Tel: +65-6592-0792 www.technolas.com – www.bausch.com Near Vision Intermediate Vision Far Vision SUPRACOR ™ SUPRACOR ™ TECHNOLAS LASIK treatment for Presbyopia OŽer your patients a customized treatment for presbyopia with a perfectly balanced near, intermediate and far vision. >>> Unique varifocal presbyopia treatment >>> Excellent far, intermediate and near vision >>> Sophisticated algorithm minimizing induction of undesired aberrations >>> Designed for the full refractive treatment range: hyperopia (CE-marked), myopia*, emmetropia* >>> Suitable for subsequent enhancements Perfectly balanced * SUPRACOR is CE marked. SUPRACOR for myopic, emmetropic, and post-LASIK patients is currently in clinical evaluation. SUPRACOR is NOT approved for use in the US. Technolas Excimer 217P is NOT approved for use in the US. Some of the products and/or specific features as well as the procedures featured in this document may not be approved in your country and thus may not be available there. Design and specifications are subject to change without prior notice as a result of ongoing technical development. Please contact our regional representative regarding individual availability in your respective market. SUPRACOR is a trademark of Bausch & Lomb Incorporated or its a£liates. kbcomunicacion. BLT-007/02-2013 ©2013 TECHNOLAS Perfect Vision GmbH. All rights reserved. New SUPRACOR Advert Eyeworld Asia 2013:BLT 5/6/13 16:43 Página 1 “We asked for physicians’ subjective impressions,” Mr. Mahdavi said. “What it points out is that doctors believe their premium market is expanding, and the laser as well as intraoperative aberrometry is helping increase the appeal to consumers willing to pay for services beyond what’s typically covered.” return on investment According to the respondents, 59% of the single-surgeon centers (13/22) and 95% of the multi- surgeon centers (41/43) are surpassing the breakeven point of 19 cases a month. On average, those centers are performing 57 cases a month with the laser, with most performing somewhere between 19 and 60 cases (although 17 centers perform between 61 and 100 cases a month with the laser). Most centers purchased the femtosecond laser, with only 7% leasing the equipment. A good number of respondents (83%) have a positive outlook on the return on investment or believe the volume has already surpassed the breakeven point. Although a smaller percentage, 3% of respondents said the laser has already paid for itself. Lastly, on a scale of 0 (very unlikely) to 10 (very likely), 42% said they were very likely (a score of 9 or 10) to recommend their peers get involved with the technology. According to Mr. Mahdavi, this annual survey is helping demystify the economics around acquiring the laser for a surgical practice. The data, coming directly from users, are very powerful at providing an accurate picture of the real world adoption of this technology, he said. Sponsors of the survey were Alcon (Fort Worth, Texas, USA/ Hünenberg, Switzerland), Bausch + Lomb (Rochester, NY, USA), OptiMedica (Sunnyvale, Calif., USA), and LENSAR (Orlando, Fla., USA). EWAP Contact information Mahdavi: shareef@sm2strategic.com